The best and worst performing ASX 200 healthcare shares of 2021

The pandemic hasn't been a tailwind for many medical companies.

S&P/ASX 200 Index (ASX: XJO) healthcare shares have largely performed well in 2021.

Of the 13 companies categorised as ASX 200 healthcare shares, 10 are in the black for the calendar year while only 3 are showing losses.

Additionally, 7 of the 13 ASX 200 healthcare shares are beating the performance of the index, which has gained just under 13% year-to-date.

Below we take a look at the best and worst performer so far this year.

best and worse asx shares represented by green best button and red worst button

Image source: Getty Images

At the bottom of the 2021 list

The worst ASX 200 healthcare share performer so far in 2021 is Polynovo Ltd (ASX: PNV).

Year-to-date, Polynovo's share price is down 44%. The medical device company is currently trading for $2.21 per share.

Polynovo hit turbulence early in the year when its half year financial results for the 6 months ending 31 December 2020, while showing sales growth, came in below guidance. Shares fell by 31% in January

COVID-19, a boon for some healthcare companies, has worked against this one.

The company depends on its access to surgeons and ongoing elective surgeries for growth. In May, shares suffered another sharp fall after the company reported a slowdown on both fronts due to the pandemic.

Top ASX 200 healthcare share performer in 2021

Coming in at the top of the list for ASX 200 healthcare shares in 2021 is Pro Medicus Limited (ASX: PME).

The healthcare imaging software and services provider's share price is up 59% year-to-date, currently trading for $55.76.

Pro Medicus kicked off the New Year well, with the announcement of a major new contract win on 13 January for its Visage Imaging business.

The 7-year contract was signed with Intermountain Healthcare, the largest medical services provider in the US state of Utah. The company estimated the value of the contract at $40 million.

Pro Medicus shares gained 22% in January.

Shares enjoyed another boost in May with the announcement of another new contract win on 13 May. The 8-year deal with The University of Vermont Health Network in the US state of Vermont was valued at $14 million.

The company's share's price has gained 37% since it released that announcement.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended POLYNOVO FPO and Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »